Page 21 - Aet News Today

AWS is funneling an additional $20 million into its health equity initiative, bringing the company’s total investment in the program to $60 million. As AWS continues to advance the mission of this program, the company is focusing on three main priorities: increasing access to high quality care, building resilient communities, and mitigating the harmful effects of climate change.

GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it's important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.

UnitedHealthcare recently launched UHC Hub, which helps self-funded employers manage multiple health solutions and employees gain access to these solutions.

After experiencing firsthand the shortcomings of existing public and private programs to treat children's developmental delays, Jen Wirt founded a startup called Coral Care. The company, which announced its official launch on Tuesday, brings pediatric developmental specialty care into families’ homes.

Cherish Health recently launched Cherish Serenity, a device that sits in the home and can detect falls across multiple rooms. If there is an emergency, it will notify a caregiver or response center for help.

Eli Lilly said its experimental gene therapy restored hearing in a boy born with profound hearing loss. The results for this experimental treatment come three months after Regeneron Pharmaceuticals reported early but encouraging data for its hearing loss gene therapy.

Panel discussions will include investment trends, women's health, value-based care, employer health and more. Startups will also have the opportunity to meet with investors as part of our Ask the Investor program. The conference will be held May 21-22 at the Ritz Carlton in Chicago. Register today!

CG Oncology’s upsized IPO will support pivotal testing of cretostimogene, an oncolytic virus for non-muscle invasive bladder cancer. The clinical program spans tests of the engineered virus as a monotherapy and as part of combination treatments.

Despite the significant challenges to improving U.S. health outcomes while reducing healthcare spending, I am heartened by the exciting ways in which government organizations and the private sector are innovating and deploying new technologies that can achieve these goals.

Key trends such as the resilience of the emerging biopharma space, the complexities of Medicare, and the revolutionary role of data and AI are shaping the future of the industry.